Pharmacological treatments for alcohol use disorder remain significantly underprescribed despite clear clinical guidelines, according to a review published in JAMA. The chronic and recurring condition involves a loss of control over intake, intense cravings, and persistent use despite physical, psychological, and social consequences. Chronic heavy drinking contributes directly to liver cirrhosis, cardiovascular diseases, accidental injuries, and multiple types of cancer, including cancers of the oral cavity, esophagus, breast, colon, and liver.
Three medications hold regulatory approval for treating the disorder: naltrexone, acamprosato (acamprosate), and disulfiram. The clinical review highlights how physicians should select these therapies based on individual patient characteristics and treatment goals, rather than relying on a one-size-fits-all approach.
Naltrexone Targets Heavy Drinking Episodes
Naltrexone functions as an opioid receptor antagonist that diminishes the reinforcing effects of alcohol, helping patients cut down on heavy drinking episodes. Clinicians typically prescribe it for oral use, though extended-release injectable formulations are available in certain regions. It proves especially useful for patients whose initial goal is reducing heavy consumption rather than maintaining immediate, complete abstinence.
Before prescribing naltrexone, physicians must verify that patients do not use opioid medications, because the drug can precipitate withdrawal and block opioid analgesia. Clinicians must also evaluate liver function, particularly in patients with advanced liver disease. Mild to moderate adverse effects commonly include nausea, headaches, and gastrointestinal discomfort.
Acamprosate Supports Long-Term Abstinence
Acamprosate targets neurochemical mechanisms linked to brain adaptations from chronic alcohol use, specifically acting on excitatory and inhibitive neurotransmission systems. Its primary clinical utility lies in helping patients maintain abstinence after they stop drinking. The medication bypasses the liver metabolism pathways utilized by other treatments, making it a viable option for patients with liver disease.
Because the kidneys clear the drug primarily through renal excretion, acamprosate is contraindicated in severe renal impairment. The medication also requires multiple daily doses, which can complicate patient adherence. Choosing between acamprosate and naltrexone depends on whether the primary goal is stable abstinence or reduced heavy drinking, alongside individual patient preferences and co-occurring conditions.
Disulfiram Relies on Behavioral Deterrence
Disulfiram inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate in the body if a patient consumes alcohol. This reaction triggers flushing, nausea, vomiting, palpitations, hypotension, and severe discomfort, meaning the drug works primarily through deterrence. Unlike naltrexone and acamprosate, disulfiram’s effectiveness depends almost entirely on strict adherence and the patient’s informed consent.
The medication suits highly motivated individuals who have adequate social supervision, but it requires extreme caution in patients with specific cardiovascular diseases, psychiatric disorders, or liver abnormalities. Clinicians must not use it without informed consent or treat it as a standalone solution for a complex, multifactorial disease.
Integrating Medication Into Comprehensive Care Plans
Pharmacotherapy provides better opportunities for recovery when combined with psychological interventions, clinical monitoring, and social support. Treatment protocols require thorough evaluations of disorder severity, past complicated withdrawals, suicide risk, co-occurring illnesses, and family support systems. Clinicians must also separate the acute management of alcohol withdrawal syndrome from the long-term prevention of relapses, as both phases demand distinct pharmacological strategies.
Regular follow-up appointments allow care teams to review treatment goals, monitor adherence, track side effects, and evaluate consumption patterns without viewing a relapse as definitive failure. The new review emphasizes that effective medical treatments exist for alcohol use disorder, but healthcare systems must incorporate them more frequently into structured, individualized, and sustained care models.